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Quantitative assessment of
microvasculopathy in arcAb mice with
USPIO-enhanced gradient echo MRI
Jan Klohs1,2,*, Andreas Deistung3,*, Giovanna D Ielacqua1,
Aline Seuwen1, Diana Kindler1, Ferdinand Schweser4,5,
Markus Vaas1,2, Anja Kipar6, Ju¨rgen R Reichenbach3,7,8,9 and
Markus Rudin1,2,10
Abstract
Magnetic resonance imaging employing administration of iron oxide-based contrast agents is widely used to visualize
cellular and molecular processes in vivo. In this study, we investigated the ability of R2 and quantitative susceptibility
mapping to quantitatively assess the accumulation of ultrasmall superparamagnetic iron oxide (USPIO) particles in the
arcAb mouse model of cerebral amyloidosis. Gradient-echo data of mouse brains were acquired at 9.4 Tafter injection of
USPIO. Focal areas with increased magnetic susceptibility and R2 values were discernible across several brain regions in
12-month-old arcAb compared to 6-month-old arcAb mice and to non-transgenic littermates, indicating accumulation of
particles after USPIO injection. This was concomitant with higher R2 and increased magnetic susceptibility differences
relative to cerebrospinal fluid measured in USPIO-injected compared to non-USPIO-injected 12-month-old arcAb mice.
No differences in R2 and magnetic susceptibility were detected in USPIO-injected compared to non-injected 12-month-
old non-transgenic littermates. Histological analysis confirmed focal uptake of USPIO particles in perivascular macro-
phages adjacent to small caliber cerebral vessels with radii of 2–8 mm that showed no cerebral amyloid angiopathy.
USPIO-enhanced R2 and quantitative susceptibility mapping constitute quantitative tools to monitor such functional
microvasculopathies.
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Introduction
Over the past several years, there has been an increasing
interest and eﬀort in developing magnetic resonance
imaging (MRI) assays to visualize cellular and molecu-
lar processes in vivo. To this end, iron oxide particle-
based contrast agents like superparamagnetic iron
oxide (SPIO) or ultrasmall superparamagnetic iron
oxide (USPIO) nanoparticles have been used.1
Cellular MRI is performed either by intravenous injec-
tion of iron oxide nanoparticles, which are subse-
quently taken up by phagocytic cells, or by adoptively
transferring cells, which have been exogenously labeled
with the nanoparticles. Iron oxide particle-based con-
trast agents increase the transverse relaxation rate by an
amount R2,CA and alter the local magnetic suscepti-
bility (CA), which enhances the reversible fraction to
the transverse relaxation rate by R2’,CA and thereby
signal dephasing. Thus, the local eﬀective transverse
relaxation rate R2,CA of a contrast agent experiment
extracted from a gradient echo (GRE) experiment is
given by the sum of intrinsic contributions from the
native tissue (R2,i) and the contrast agent (R

2,CA),
i.e., R2,CA¼R2,iþR2,CA¼R2,iþR2,CAþR2’,CA,
and depends sensitively on the presence of iron particles
due to their high intrinsic transverse relaxivity.
Consequently, voxels that contain cells with ingested
iron particles are displayed with reduced intensity
(hypointense) on T2- or T

2-weighted images.
Several MRI methods have been developed for
quantiﬁcation of iron oxide-based contrast agents.
One common approach is relaxometry, i.e., the analysis
of the magnitude signal decay to extract transverse
relaxation rates R2,CA or eﬀective transverse relaxation
rates R2,CA of iron oxide particles in the tissue.
2,3
Although many reports have demonstrated a linear
relationship between R2,CA or R

2,CA and iron concen-
tration,4,5 there are additional variables that inﬂuence
relaxation, such as size, intravoxel distribution and
compartmentalization of the particles, or changes in
the composition of the surrounding tissue.3,5,6 Thus,
relaxometric procedures may misestimate iron concen-
trations. Alternatively, phase information obtained
from GRE data can be used for quantitative analysis
of iron content since iron oxide nanoparticles give rise
to local changes of magnetic susceptibility, which are
detected as changes in signal phase.7–9 However, direct
correlation between phase and iron content is impeded
due to the non-local relationship between an arbitrary
magnetic susceptibility distribution and its eﬀect on the
resulting magnetic ﬁeld.10 Therefore, iron quantiﬁca-
tion based solely on phase is only reliable if the distri-
bution of iron oxide particles is of a simple,
geometrically regular shape, such as a sphere.9
Quantitative susceptibility mapping (QSM), a
recently introduced post-processing technique for GRE
phase information, promises to overcome this limitation.
QSM converts phase images into maps of bulk magnetic
susceptibility distribution, which can be analyzed dir-
ectly.11–13 The beneﬁt of QSM in quantifying the
amount of iron oxide nanoparticles in biological tissue
has recently been demonstrated for nanoparticles
injected into skeletal muscle ex vivo,14 as well as
in vivo with nanoparticles that had been functionalized
against the intercellular adhesion molecule-1 in a lipopo-
lysaccharide-induced model of acute inﬂammation.15
In the present work, we demonstrate the feasibility
of QSM to visualize and quantify USPIO accumulation
in the brain of arcAb mice at 9.4T. The arcAb mouse
strain is a genetic model of cerebral amyloidosis and
exhibits progressive accumulation of amyloid-b (Ab)
protein in brain parenchyma and in the walls of cerebral
vessels (cerebral amyloid angiopathy, CAA) with pro-
nounced vascular remodeling.16–18 Hence, the strain is
well suited to serve as a model of hereditary cerebral
hemorrhage with amyloidosis,19 and Alzheimer’s dis-
ease.20 We evaluated the visibility of USPIO accumula-
tion on quantitative susceptibility and R2 maps and
quantiﬁed iron particle deposition bymeasuring changes
in R2 and magnetic susceptibility. Histological analysis
was performed to investigate vasculopathy and demon-
strate the cellular uptake of USPIOs in situ.
Materials and methods
Animals
All experimental procedures conformed to the national
guidelines of the Swiss Federal Act on Animal
Protection and were approved by an oﬃcial committee
(license 194/2011, Cantonal Veterinary Oﬃce, Zurich,
Switzerland). We conﬁrm compliance with the
ARRIVE guidelines on reporting animal experiments.
Transgenic (arcAb) mice and non-transgenic littermates
(NTL) of either sex were used. Animals were kept at
standard housing conditions with a 12-h dark/light
cycle and were provided with water and food ad libitum.
USPIO
P904 (Guerbet, France) is an USPIO and consists of an
iron oxide core and a hydrophilic coating of a mono-
meric organic molecule with 20 hydroxylic groups,
resulting in a mean hydrodynamic diameter of
21 nm.21 P904 is cleared from the blood with a rate of
0.73mL/min/kg.22 As P904 is less prone to liver uptake
compared to SPIO its blood half-life and thus its
uptake capacity by macrophages is increased.23 The
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P904 that is taken up by macrophages has been found
to be degraded to non-toxic ferritin.24
Magnetic resonance imaging
The study was performed using four batches of animals:
The ﬁrst batch consisted of six arcAb mice and six NTL
of 5.8–6.5 months of age and was assessed with MRI
without USPIO injection. The second batch consisted of
ﬁve arcAb mice and six NTLs of 6–6.7 months of age
and comprised animals from the ﬁrst batch that were,
after one week of recovery, assessed with MRI a second
time 18h after intravenous injection of P904 (1000mmol/
kg body weight). The third batch consisted of 11 arcAb
mice and 12 NTL of 9.6–12.2 months of age that were
measured with MRI without USPIO injection. The
fourth batch of mice consisted of 11 arcAb mice and 7
NTL of 11.5–12.5 months of age which were assessed
with MRI 18h after intravenous injection of P904.
MRI data were acquired on a Bruker BioSpec 94/30
(Bruker BioSpin GmbH, Germany) small animal MR
system operating at 9.4T. The system was equipped
with a cryogenic receive only 2 2 phased-array
mouse head surface coil (Bruker BioSpin AG,
Fa¨llanden, Switzerland). A linearly polarized volume
resonator was used for homogeneous transmission.
Anesthesia was induced with 3 % isoﬂurane (Abbott,
Cham, Switzerland) in a 4:1 air/oxygen mixture. The
mice were endotracheally intubated and mechanically
ventilated during the measurements with 80 breaths/
minute and a respiration cycle of 25 % inhalation
and 75 % exhalation (MRI-1 Volume Ventilator;
CWI Inc., Ardmore, USA) using 1.2 % isoﬂurane.
Body temperature was monitored with a rectal tem-
perature probe (MLT415, ADInstruments) and kept
at 36.0 0.5C using a warm-water circuit integrated
into the animal support (Bruker BioSpin). Anatomical
reference data acquired in coronal and sagittal orienta-
tions served for accurate positioning of the animal’s
head. Global ﬁrst-order shimming followed by ﬁeld-
map-based local shimming was performed on the
mouse brain using the automated MAPshim routine
to reduce ﬁeld inhomogeneities. A 3D multi-echo
GRE sequence was applied using a ﬁeld-of-view of
25.6mm 25.6mm 8mm and an acquisition matrix
of 256 256 80, resulting in an eﬀectively isotropic
spatial resolution of 100 mm 100 mm 100 mm. Four
echoes were recorded (echo times (TE)¼ 3.2ms/
7.8ms/12.4ms/17ms) with repetition time¼ 80ms, ﬂip
angle¼ 15, bandwidth¼ 78 kHz, monopolar echo
readout, and no averaging within an acquisition time
of 20min.
The relaxivity (r2) and the molar susceptibility of
P904 at a magnetic ﬁeld strength of 9.4 T were
determined at room temperature (T¼ 295K) by
measuring diﬀerent contrast agent concentrations in dis-
tilled water (cP904¼ 0.03mM/0.06mM/0.12mM/
0.24mM/1.2mM/2.4mM). The diﬀerent aqueous solu-
tions were guided through a tube that was immersed into
a water bath. For each P904 concentration, the experi-
mental setup was imaged using a 3D multi-echo GRE
sequence with the same geometry as for the mouse head.
Six echoes were recorded (echo times (TE)¼ 3.0ms/
6.6ms/10.2ms/13.8ms/17.4ms/21.0ms) with repetition
time¼ 80ms, ﬂip angle¼ 15, bandwidth¼ 78 kHz,
monopolar echo readout, and no averaging.
Histology and immunohistology
Upon completion of MRI measurements, mice were
transcardially perfused with phosphate-buﬀered saline
(PBS, pH 7.4), followed by 4% buﬀered paraformalde-
hyde (PFA; pH 7.4) for ﬁxation. Brains were removed
from the skull and ﬁxed for another 24 h, after which
horizontal slices (approx. 2mm) of the entire brain were
prepared and embedded in paraﬃn wax. Sections
(4 mm) were prepared and stained with hematoxylin-
eosin (HE) for histopathological assessment and with
Perls’ Prussian blue for the demonstration of iron
(Fe3þ). Brieﬂy, slides were incubated in a 1% potassium
ferrocyanide and 0.5% hydrochloric acid solution, fol-
lowed by incubation with a 0.1% solution of nuclear
fast red with aluminum sulfate for nuclear counter-
staining. For diaminobencidine (DAB) enhancement
of the Perls’ Prussian blue stain, slides were washed in
TBS-Tween and incubated for 15min with Peroxidase
Blocking Solution (Dako), then washed with tap water
and counterstained with hemalaun for 1 s.
Demonstration of iron within macrophages/microglial
cells was achieved by staining with Perls’ Prussian blue
(blue), nuclear fast red, and immunohistology for Iba1.
Consecutive sections were used for triple immunohis-
tology, using rat anti-mouse CD31 (PECAM-1; clone
SZ31, Dianova, Germany) for the demonstration of
endothelial cells, rabbit anti-Iba1 (anti-peptide anti-
body, Wako Pure Chemicals) for the staining of micro-
glial cells/macrophages, and mouse anti-beta amyloid
(Ab; clone 6E10, BioLegend) for the demonstration of
Ab deposition. Antigen retrieval was achieved by incu-
bation in Retrieval-Buﬀer 2 (Leica AR9640) for 45min
at 100C (CD31) and for 10min at 95C (Iba1).
Sections were incubated for 30min at room tempera-
ture with the primary antibodies diluted 1:200 (anti-
CD31), 1:2,500 (anti-Iba1), and 1:5,000 (anti-Ab) in
Antibody Diluent (Leica AR9352) followed by incuba-
tion with rabbit anti-rat Ig (1:1,000, Abcam) and the
Reﬁne AP-Kit with new fast red as chromogen (Leica)
for CD31, the Reﬁne HRO kit and DAB as chromogen
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for Iba1, and the Reﬁne HRP-kit (Leica) and perma-
blue as chromogen (Diagnostic Biosystems) for Ab.
MRI data processing
Single-channel GRE magnitude images were combined
using the sum-of-squares method,25 whereas single-
channel GRE phase images were combined by taking
the argument of the complex summed single-channel
images after subtracting the channel-dependent phase
oﬀset estimated in the center of the three-dimensional
volume of the ﬁrst echo.26 Quantitative susceptibility
maps were computed based on these combined phase
images. To this end, the combined phase images for
each echo were unwrapped using a 3D best-path algo-
rithm,27 divided by 2  TEð Þ to obtain the Larmor fre-
quency variation in Hz, and then combined across the
diﬀerent TEs in an optimized way that takes into
account the local echo-time dependent contrast-to-
noise ratio of the Larmor frequency images.28
Background frequency contributions were eliminated
using sophisticated harmonic artifact removal for
phase data (SHARP),11 with 10 diﬀerent spherical ker-
nels with varying radii ranging from 100mm to
1000 mm,29 employing a regularization parameter for
truncated singular value decomposition of 0.05.
Susceptibility mapping was performed based on
SHARP-processed frequency images using homogene-
ity-enabled incremental dipole inversion (HEIDI).12
Maps of the eﬀective transverse relaxation rate, R2,
were calculated from the magnitude images using the
power method.30,31 The squared magnitude signal
decay S ~r,TE
 2
of the multi-echo GRE scan was used
for the regression and the following function was ﬁtted
using the logarithmic calculus
S ~r,TE
 2¼ S0 ~r
 2 exp 2  TE  R2 ~r
   ½1	
where S0 ~r
 
is the (unknown) signal intensity at TE¼ 0
and ~r is the position vector.
Data analysis
Generated maps were excluded from further analysis in
case of artifacts (the number of analyzed maps for each
group is given in Table 1). Three-dimensional volumes-
of-interest (VOIs) were identiﬁed on magnitude images
covering the olfactory bulb, cerebral cortex, striatum,
hippocampus, thalamus, brain stem, and the ventricles
using MRIcron (www.sph.sc.edu/comd/rorden/mri-
cron/). Analysis was performed blinded with regard to
the experimental group. VOIs were applied to R2 and
susceptibility maps and mean values were calculated for
each region. The maps were visually inspected and in
cases of apparent artifacts (e.g., induced by insuﬃcient
shimming) VOI values were excluded from analysis. All
susceptibility values were referenced to the magnetic
susceptibility measured in the ventricles. In addition,
in one 12-month-old arcAb mouse with and one
mouse without P904 injection VOIs were manually
deﬁned in 10 cortical vessels to estimate the amount
of iron uptake. These vessels were identiﬁed based on
their increased intensity on magnetic susceptibility
maps and their tubular shape was assessed by following
the vessel path across several adjacent slices.
Linear regression between P904 concentration
(cP904) and the magnetic susceptibility diﬀerence with
respect to the surrounding water and between cP904
and the R2 value of the P904 solution was applied to
determine the molar susceptibility and r2, respectively
(Supplementary Figure 1). Using the determined molar
susceptibility, the measured susceptibility diﬀerences
between arcAb mice with and without P904 injection
in diﬀerent brain areas were converted into iron esti-
mates as an indicator for the USPIO concentration
(cP904,arcA).
Results
GRE data of 6 - and 12-month-old NTL and arcAb
mice were acquired without and 18 h after intravenous
injection of P904. Representative horizontal sections of
R2 and magnetic susceptibiltiy maps are displayed in
Figure 1. In NTL of both ages, non-injected and P904-
injected 6-month-old arcAb mice and non-injected
12-month-old arcAb mice only few focal areas were
discernible with increased magnetic susceptibility and
R2 values. These areas most likely constitute venous
structures with a high amount of paramagnetic deoxy-
hemoglobin.32 In the brains of 12-month-old arcAb
mice, however, a large number of foci of increased R2
and magnetic susceptibility were observed 18 h after
P904 administration, indicating accumulation of
USPIO particles. Axial sections of susceptibility maps
revealed accumulation of USPIO particles in the cere-
bral cortex, striatum, and hippocampus (Figure 2).
To obtain a quantitative estimate of USPIO accu-
mulation, we performed VOI analysis of susceptibility
and R2 for diﬀerent anatomical regions (Table 1).
Statistical analysis was only performed for 12-month-
old mice because of the small group size of 6-month-old
mice. R2 and  values for each genotype were com-
pared with and without P904 injection. In NTL, there
were no signiﬁcant diﬀerences in R2 and  for all
investigated brain regions. In contrast, signiﬁcantly
higher R2 values were measured in P904-injected
arcAb mice compared to non-injected arcAb mice in
the olfactory bulb, cerebral cortex, hippocampus, stri-
atum, and thalamus but not in the brain stem.
Signiﬁcantly higher magnetic susceptibility diﬀerences,
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, relative to cerebrospinal ﬂuid were measured in the
cerebral cortex, hippocampus, and striatum of injected
compared to non-injected arcAb mice, but not in the
olfactory bulb, thalamus, and brain stem. As a refer-
ence for the quantitative assessment, we analyzed the
P904 eﬀect on the quantitative MRI parameters in
voxels that fully covered cortical vessels of a
12-month-old arcAb mouse with and without P904
injection (Table 1). Signiﬁcantly higher R2 and 
values were observed after P904 administration. To
transfer the estimated susceptibility diﬀerences between
arcAb mouse with and without P904 injection into
USPIO concentrations (Table 1), we characterized the
contrast agent at a magnetic ﬁeld strength of 9.4 T in an
experimental setup (Supplementary Figure 1) and
determined its molar susceptibilty to be 0.0216 ppm*l/
Table 1. VOI analysis of R2 and susceptibility maps (values of  are given relative to the mean susceptibility in CSF).
R2 (s
1)  (ppm) cP904,arcA
(mmol/l)
wt arcAb wt arcAb
6 months of age, no P904
Olfactory bulb 30.1 0.8 (6) 29.7 0.7 (6) 0.030 0.007 (6) 0.032 0.005 (6)
Cortex 29.7 1.4 (6) 28.6 0.4 (6) 0.029 0.006 (6) 0.031 0.006 (6)
Hippocampus 28.2 1.3 (6) 27.3 0.3 (6) 0.032 0.005 (6) 0.034 0.004 (6)
Striatum 31.0 0.9 (6) 31.3 0.7 (6) 0.031 0.006 (6) 0.033 0.006 (6)
Thalamus 33.5 1.6 (5) 32.2 1.0 (6) 0.032 0.006 (6) 0.034 0.005 (6)
Brain stem 38.3 2.1 (5) 38.7 2.3 (6) 0.028 0.006 (6) 0.031 0.006 (6)
6 months of age, with P904
Olfactory bulb 34.2 6.6 (5) 33.3 5.4 (4) 0.028 0.012 (5) 0.034 0.009 (4) –
Cortex 33.7 7.0 (5) 32.5 5.5 (4) 0.027 0.012 (5) 0.027 0.011 (4) 186
Hippocampus 30.6 6.4 (5) 31.1 4.0 (4) 0.032 0.010 (5) 0.029 0.009 (5) 232
Striatum 35.7 10.3 (5) 37.0 7.9 (4) 0.028 0.016 (5) 0.028 0.010 (4) 232
Thalamus 38.9 11.4 (5) 38.8 8.9 (4) 0.030 0.012 (5) 0.029 0.011 (4) 232
Brain stem 42.5 12.3 (5) 46.9 9.1 (4) 0.026 0.014 (5) 0.026 0.012 (4) 232
12 months of age, no P904
Olfactory bulb 32.5 1.2 (12) 31.2 1.0 (9) 0.023 0.008 (12) 0.030 0.007 (10)
Cortex 30.1 0.8 (11) 30.2 1.8 (9) 0.024 0.006 (12) 0.029 0.006 (10)
Hippocampus 28.8 1.3 (12) 28.9 2.1 (9) 0.026 0.006 (12) 0.032 0.006 (10)
Striatum 32.2 0.8 (12) 31.9 0.8 (9) 0.025 0.006 (12) 0.034 0.006 (9)
Thalamus 33.9 1.0 (12) 33.6 1.4 (9) 0.027 0.006 (12) 0.032 0.006 (10)
Brain stem 39.8 1.5 (12) 40.9 2.0 (7) 0.022 0.006 (12) 0.028 0.006 (10)
Cortical vessels 58.1 12.5 (1) 0.002 0.01 (1)
12 months of age, with P904
Olfactory bulb 31.8 2.1 (7) 34.1 2.5 (11)* 0.029 0.004 (6) 0.025 0.008 (11) 232
Cortex 29.0 1.8 (7) 32.7 3.1 (11)* 0.029 0.005 (6) 0.023 0.008 (10)* 278
Hippocampus 27.7 1.7 (7) 31.4 2.2 (11)* 0.030 0.004 (6) 0.025 0.007 (11)* 325
Striatum 33.4 2.1 (7) 35.8 3.6 (11)* 0.028 0.004 (6) 0.028 0.004 (11)* 278
Thalamus 33.1 2.6 (7) 36.9 3.1 (11)* 0.031 0.004 (7) 0.026 0.009 (10) 278
Brain stem 38.1 3.1 (7) 44.5 4.6 (11) 0.028 0.005 (7) 0.023 0.007 (10) 232
Cortical vessels 118 10 (1) 0.02 0.015 (1) 1020
Mean value and standard deviations of R2* and magnetic susceptibility " for individual brain regions across animals. Mean values and standard
deviations for cortical vessels were obtained across 10 vessels in one 12-month-old arcAb mouse with and without P904 injection. The concentrations
of P904 in arcAb mice (cP904,arcA) were estimated based on the susceptibility differences between arcAb mice with and without USPIO administration.
The number in brackets gives the group size. * indicates statistical significant differences between P904 versus non-injected 12-month-old mice of the
same genotype using Student’s t-test (p
 0.05).
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mmol and its r2 to be 84.3 s
1 * l/mmol. Our molar
susceptibilitiy is substantially smaller than 2.3 ppm *
l/mmol measured by Wang et al.33 at a magnetic ﬁeld
strength of 2.35T and may be explained by a non-linear
relationship between the magnetization of the USPIO
and the applied magnetic ﬁeld strength.
Histological analysis was used to investigate vascu-
lopathy and cellular uptake of USPIOs. This analysis
did neither reveal pathological changes in the 6-month-
old arcAb mice nor in the NTL. However, in all
6-month-old arcAbmice, small caliber vessels occasion-
ally exhibited a variable degree of vascular Ab depos-
ition, ranging from very small granular over larger
patchy to circular deposits, but showed no parenchy-
mal Ab deposition (Figure 3(a)). Cerebral vessels were
not associated with the presence of activated perivascu-
lar macrophages and there was no evidence of iron
uptake.
The brains of both USPIO injected and non-injected
12-month-old arcAb mice revealed vascular changes
consistent with CAA (Figure 3(c)),17 together with
multifocal parenchymal Ab plaques with associated
microgliosis (Figure 3(f)), which was most prominent
in the cortex. Immunohistology identiﬁed a variable
degree of vascular Ab deposition in the walls of small
caliber vessels, which was patchy or circular and often
extended over a considerable length of the vessels
(Figure 3(d) and (e)). Around more severely aﬀected
vessels, Ab deposits stretched into the adjacent paren-
chyma, where one or occasionally several Iba1-positive
cells with the morphology of activated microglia were
found (Figure 3(d) and (e)). Immunohistology also con-
ﬁrmed the multifocal parenchymal deposits as dense Ab
aggregates which, as previously described,34 were sur-
rounded by or intermingled with Iba1-positive, acti-
vated microglial cells (see Figure 3(f)). In USPIO
injected mice, a few small foci were identiﬁed, in
which individual small caliber vessels (radius: 2–8mm)
exhibited one or a few perivascular elongated cells that
contained iron-positive material, consistent with cellu-
lar uptake of USPIOs (Figure 3(g) and (h)). Combined
Perls’ Prussian blue and immunohistological staining
for Iba1 conﬁrmed these cells as macrophages.
However, their morphology was consistent with
perivascular macrophages and not with activated
microglia.35 These vessels did not exhibit any
histopathological changes, in particular there was no
morphological evidence of CAA. In contrast, in
CAA-aﬀected vessels we did not detect iron-positive
material. Rarely, individual iron-containing cells with
the morphology of macrophages/microglial cells were
also found in the parenchyma within these areas
(Figure 3(g), arrows).
Discussion
GRE MRI techniques are highly sensitive to the under-
lying magnetic susceptibility distribution. Iron oxide-
based contrast agents are used as label for cellular
MR studies because they generate localized variations
Figure 1. (a) Representative horizontal sections of R2 maps of 6 - and 12-month-old non-transgenic littermates (NTL) and arcAb
mice. (b) Corresponding quantitative susceptibility maps. Only in the 12-month-old arcAb mouse focal areas of R2 values and high
magnetic susceptibility are revealed 18 h after intravenous injection of P904, indicating accumulation of P904. The þ and – symbol for
P904 (last column) indicates MRI with and without USPIO injection, respectively.
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in magnetic susceptibility () and R2 (or R

2) values,
thereby enhancing signal dephasing. These eﬀects are
usually detected as hypointensities (negative contrast)
on T2- or T

2-weighted magnitude images, which how-
ever do not provide quantitative information on the
amount of the accumulated contrast agent. In the cur-
rent study, we demonstrated the ability of R2 mapping
and QSM not only to visualize but also to quantify
USPIO accumulation in the arcAb model of cerebral
amyloidosis. We observed nanoparticle accumulation
speciﬁcally in certain brain regions of 12-month-old
arcAb mice after injection of P904 (Figures 1 and 2).
Local values of tissue R2 were increased by 2.5 to
3.9 s1, and  values were 0.004 to 0.006 ppm higher
in brain regions with USPIO accumulation. Based on
the measured molar susceptibility value of P904 of
0.0216 ppm/mM, we estimated that USPIO contrast
agent concentration ranged from 232 to 325 mmol/l
(Table 1).
Quantifying USPIO concentrations on the basis of
R2 and susceptibility changes in vivo is, however, chal-
lenging because variations in these two parameters can
be governed by a number of factors. In homogeneous
solutions changes in R2,CA or R

2,CA and magnetic
susceptibility depend linearly on the iron concentra-
tion,4,5 whereas in biological samples these changes
are also inﬂuenced by intrinsic R2,i (R

2,i) and magnetic
susceptibility contributions from the tissue, which
might be altered by changes in the tissue microstruc-
ture, e.g., due to ageing or in the case of arcAb mice by
amyloidosis.36 Since these eﬀects on R2 and  are
unknown a priori, we acquired baseline GRE data of
mice not injected with P904 to enable estimation of the
eﬀect of USPIO accumulation.
The eﬀect of an injected iron oxide contrast agent on
R2 and  values will be reduced due to partial volume
eﬀects, as the volume fraction containing the contrast
agent is small, e.g., perivascular macrophages at small
caliber vessels compared to the voxel dimension.
This might explain why the eﬀects on R2 and 
values after P904 injection are relatively small. This
becomes obvious when conﬁning the analysis to VOIs
comprising essentially cortical vessels only. A mean sus-
ceptibility diﬀerence of 0.022 ppm was observed in cor-
tical vessels between a 12-month-old arcAb mouse with
and without P904 administration, which corresponds to
a local P904 concentration of 1020mmol/l. Taking into
account the voxel volume of 1 nl we estimate an amount
of substance of 1.02 pmol which corresponds to 57 pg of
iron (molar weight of iron is 56 g/mol). This is substan-
tially larger than the corresponding values found for a
large cortical VOI, for which  was found to be
0.005 ppm, corresponding to 15.6 pg of iron. This
might still be an underestimation as the USPIOs are
not distributed across the whole vessel but rather con-
ﬁned to the vessel wall. Obviously, such analyses are
only applicable to regions in which resolved vascular
structures are comparable in size with the voxel dimen-
sions. We measured the radii of vessels to which
USPIOs accumulate on Perls’ Prussian blue and
nuclear fast red double-stained slices to range from
2 to 8 mm, which is smaller than the typical MRI
voxel size. In these cases, the aﬀected vessels cannot
be reliably identiﬁed and MRI analysis is limited to
tissue VOIs.
We also found diﬀerences in the sensitivity between
R2 mapping and QSM. While with R

2 mapping we
found signiﬁcantly increased values in ﬁve brain
regions, with QSM we detected an increase in  in
only three regions (Table 1). Due to non-local eﬀects
of changes in susceptibility on the magnetic ﬁeld, a
region experiencing enhanced signal dephasing by the
presence of USPIO particles extends beyond the
dimensions of the magnetic inclusion (blooming
Figure 2. (a) Axial brain sections of susceptibility maps of a
12-month-old non-transgenic littermate (NTL) and an arcAb
mouse taken at different anatomical locations. The white dashed
boxes indicate the anatomical region highlighted in the enlarged
sections (b). (b) Enlarged images reveal areas of high susceptibility
in the NTL animal, presumably veins, that contain a high amount
of paramagnetic deoxyhemoglobin (black arrow). Focal areas of
high susceptibility in cortical regions, the striatum, and hippo-
campus of the arcAb mouse are indicative of USPIO particle
accumulation in these regions (white arrows).
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Figure 3. Histological findings in the cortex of arcAb mice and non-transgenic littermates (NTL). (a) Twelve-month-old NTL. Small
caliber vessels (CD31-positive endothelial cells: red) with Iba-1-positive (brown) perivascular macrophages (arrowhead) and Iba-1-
positive (adjacent) inactive microglial cells (arrows). (b) Six-month-old arcAb mouse. Small caliber vessels (CD31-positive endothelial
cells: red) exhibit patchy Ab deposition (blue, arrowheads). Staining for Iba-1 (brown) highlights the inactive microglial cells with their
slender processes (short arrows) and the flatter perivascular macrophages (long arrow). (c) to (h) Twelve-month-old arcAb mouse. (c)
Small caliber vessels with CAA changes on a HE stain. One vessel exhibits homogenous eosinophilic thickening of the wall (*) due to
Ab deposition. On a more severely affected vessel, the eosinophilic material spreads out into the adjacent parenchyma (arrowheads),
where activated microglial cells (arrows) are seen. (d) Triple staining of CD31, Ab, and Iba1 confirms the deposition of Ab (blue) in the
vessel walls (CD31-positive endothelial cells: red), often circular over a stretch of a vessel (arrowheads), and with an occasional
apposed activated microglial cell (arrows). (e) Closer view of affected vessels on the CD31/Ab/Iba1 triple stain, with Ab stretching
from the vessel wall into the adjacent parenchyma (arrowheads) and closely apposed activated microglial cells (arrows). (f)
Parenchymal Ab plaque. Left: The Ab plaque is represented on the HE stain by dense amorphous eosinophlic material (*) which is
surrounded by cells with the morphology of activated microglia (arrows). Right: The CD31/Ab/Iba1 triple stain reveals that the
eosinophilic material represents Ab (blue) and highlights the morphology of the associated activated microglial cells with Iba-1 (brown,
arrows). (g) Focus with a few small caliber vessels with Perls’ Prussian blue positive, iron laden perivascular macrophages (arrows) and
scattered iron laden macrophages in the parenchyma (arrowhead). Inset: Double stain for iron (Perls’ Prussian blue) and Iba-1 (brown)
confirms the iron laden cells (arrows) as macrophages. Nuclear fast red counterstain. (h) In the DAB-enhanced Perls’ stain, the shape
of the iron-laden perivascular macrophages (arrows; inset: arrowheads) is better defined, and some positive cell processes stretching
into the parenchyma can be seen (arrowheads). a, b, d–f (right): Triple immunohistology for Ab (blue), Iba-1 (brown), and CD31 (red).
Bars¼ 10mm.
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eﬀect). This may amplify the R2 increase compared to
magnetic susceptibility maps, which are largely devoid
of blooming eﬀects.
Histological analysis was performed to demonstrate
the cellular uptake of USPIOs. We found that USPIOs
target to CAA aﬀected vessels with radii between 2 and
8 mm meaning that P904 accumulates at the microvas-
culature but not at larger cerebral vessels which is in a
good agreement with the literature.37,38 Although the
actually measured radii of CAA aﬀected vessels are
lower than the radii of 10 to 40 mm reported previously
which might be due to diﬀerences in the technical
approaches,18 the current study supports the ﬁnding
that microvasculature is aﬀected by the amyloid-
induced vasculopathy.
In addition, we found that perivascular macrophages
contained iron-positive material following injection of
P904 in 12-month-old arcAb mice whereas iron-
containing cells in brain parenchyma were rarely seen
(Figure 3(g) and (h), arrow heads). This conﬁrms ﬁnd-
ings by Beckmann et al.39 who detected iron oxide par-
ticles ingested by perivascular macrophages after
intravenous injection in APP23 mice. Since, we have
not seen morphological evidence of perivascular and
parenchymal macrophage inﬁltration it is most likely
that the residing perivascular macrophages have taken
up P904 in situ.
Interestingly, Beckmann et al.39 observed a mean
number of 10 foci in the brain when assessing the
28-month-old APP23 mice with MRI, while we
observed a much higher number of foci in arcAb
already at 12 months of age. This diﬀerence might be
attributed to the diﬀerent mouse strains but also to
diﬀerences in the contrast agent. While Endorem,
which was used in the study by Beckmann et al.,39 is
a SPIO particle with a hydrodynamic diameter of
150 nm, the hydrodynamic diameter of USPIO P904
is only 21 nm.21 Although the uptake of Endorem by
phagocytes is higher compared to P904 under in vitro
conditions, the labeling eﬃciency may be reduced
in vivo due to the shorter blood half-life of Endorem.23
Beckmann et al.39 showed that iron oxide particle
accumulation depends on the accumulation of vascular
Ab by comparing contrast agent accumulations in dif-
ferent mouse strains. While they observed only minor
particle accumulation in the brains of PP23xPS45,
APP24, and APP51 mice which show very little CAA,
Endorem accumulated substantially in the brain of
APP23 mice for which the degree of CAA was mark-
edly higher. We have further analyzed the relationship
between USPIO accumulation and CAA in the current
study. In 6-month-old arcAb mice, minimal vascular
Ab deposition was observed (Figure 3(b)), while in
12-month-old animals CAA was more pronounced
(Figure 3(d) and (e)). We have previously shown that
CAA in arcAb mice results in vascular remodeling with
deposition of ﬁbrinogen, loss of smooth muscle cells,
blood–brain barrier impairment, and occurrence of
cerebral microbleeds.16–18 Surprisingly, we did not
observe iron-positive perivascular macrophages
around CAA-aﬀected vessels but only around morpho-
logically unaltered vessel without morphological evi-
dence of CAA (Figure 3(g) and (h)). An explanation
for this could be that in CAA-aﬀected vessels, despite
vascular remodeling, Ab and ﬁbrinogen deposition
might physically prevent the USPIO from extravasating
and thereby the uptake by tissue-resident macrophages.
However, the fact that non-CAA-aﬀected vessels show
uptake of P904 indicates their increased permeability
and thereby a functional vasculopathy. Using immuno-
histology, we observed activated microglia associated
with vascular and parenchymal amyloid deposition.
Activated microglia can change their microenviron-
ment by secreting for example proangiogenic factors,40
which in the vicinity of vessels might lead to blood–
brain barrier impairment and thus extravasation of
injected USPIO. We have found no evidence of Gd-
DTPA leakage using dynamic contrast-enhanced MRI
in arcAb mice,36 while blood–brain barrier damage
has been described with histology in this mouse
strain.17 Hence, the USPIO-enhanced GRE MRI
might provide a more sensitive read-out for vascular
leakage in vivo than the dynamic contrast-enhanced
MRI because of the cellular ingestion of particles by
perivascular macrophages. The mechanisms of the
functional impairment and their temporal dynamics
are not known. The eﬀect was clearly age-dependent
as it was seen in 12-month-old but not in 6-month-
old arcAb mice. USPIO-enhanced GRE MRI provides
a powerful non-invasive tool to study these vascular
lesion loads during the disease course quantitatively,
enabling a correlation with image-based read-outs of
vascular dysfunction and thus shedding more light on
the role of functional vasculopathy in the disease
pathogenesis.
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